PortfoliosLab logoPortfoliosLab logo
PACB vs. GRAB
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

PACB vs. GRAB - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Pacific Biosciences of California, Inc. (PACB) and Grab Holdings Limited (GRAB). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, PACB achieves a -29.95% return, which is significantly higher than GRAB's -33.87% return.


PACB

1D
-2.96%
1M
8.26%
YTD
-29.95%
6M
-38.21%
1Y
9.17%
3Y*
-54.65%
5Y*
-46.26%
10Y*
-17.53%

GRAB

1D
-1.49%
1M
-7.04%
YTD
-33.87%
6M
-35.92%
1Y
-27.79%
3Y*
-1.47%
5Y*
-22.42%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

PACB vs. GRAB - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
PACB
Pacific Biosciences of California, Inc.
-29.95%2.19%-81.35%19.93%-60.02%-21.13%64.07%
GRAB
Grab Holdings Limited
-33.87%5.72%40.06%4.66%-54.84%-44.56%8.16%

Correlation

The correlation between PACB and GRAB is 0.29, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.29

Correlation (3Y)
Calculated over the trailing 3-year period

0.23

Correlation (5Y)
Calculated over the trailing 5-year period

0.31

Correlation (All Time)
Calculated using the full available price history since Dec 1, 2020

0.31

Fundamentals

Market Cap

PACB:

$400.62M

GRAB:

$14.66B

EPS

PACB:

-$0.43

GRAB:

$0.09

PS Ratio

PACB:

2.47

GRAB:

4.02

PB Ratio

PACB:

3.82

GRAB:

2.25

Total Revenue (TTM)

PACB:

$160.03M

GRAB:

$3.55B

Gross Profit (TTM)

PACB:

$59.34M

GRAB:

$1.55B

EBITDA (TTM)

PACB:

-$146.34M

GRAB:

$481.00M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

PACB vs. GRAB — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PACB
PACB Risk / Return Rank: 4949
Overall Rank
PACB Sharpe Ratio Rank: 4747
Sharpe Ratio Rank
PACB Sortino Ratio Rank: 5353
Sortino Ratio Rank
PACB Omega Ratio Rank: 5050
Omega Ratio Rank
PACB Calmar Ratio Rank: 4848
Calmar Ratio Rank
PACB Martin Ratio Rank: 4747
Martin Ratio Rank

GRAB
GRAB Risk / Return Rank: 1616
Overall Rank
GRAB Sharpe Ratio Rank: 1111
Sharpe Ratio Rank
GRAB Sortino Ratio Rank: 1212
Sortino Ratio Rank
GRAB Omega Ratio Rank: 1515
Omega Ratio Rank
GRAB Calmar Ratio Rank: 2222
Calmar Ratio Rank
GRAB Martin Ratio Rank: 2121
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PACB vs. GRAB - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Pacific Biosciences of California, Inc. (PACB) and Grab Holdings Limited (GRAB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


PACBGRABDifference
Sharpe ratioReturn per unit of total volatility

+0.89

Sortino ratioReturn per unit of downside risk

+1.88

Omega ratioGain probability vs. loss probability

1.09

0.89

+0.20

Calmar ratioReturn relative to maximum drawdown

0.19

-0.58

+0.78

Martin ratioReturn relative to average drawdown

0.36

-1.05

+1.41

PACB vs. GRAB - Sharpe Ratio Comparison

The current PACB Sharpe Ratio is 0.12, which is higher than the GRAB Sharpe Ratio of -0.76. The chart below compares the historical Sharpe Ratios of PACB and GRAB, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

PACB vs. GRAB - Drawdown Comparison

The maximum PACB drawdown since its inception was -98.22%, which is greater than GRAB's maximum drawdown of -86.46%. Use the drawdown chart below to compare losses from any high point for PACB and GRAB.


Loading charts...

Drawdown Indicators


PACBGRABDifference

Max Drawdown

Largest peak-to-trough decline

-98.22%

-86.46%

-11.76%

Max Drawdown (1Y)

Largest decline over 1 year

-58.05%

-49.30%

-8.75%

Max Drawdown (3Y)

Largest decline over 3 years

-93.47%

-49.30%

-44.17%

Max Drawdown (5Y)

Largest decline over 5 years

-97.47%

-86.46%

-11.01%

Max Drawdown (10Y)

Largest decline over 10 years

-98.22%

Current Drawdown

Current decline from peak

-97.44%

-80.66%

-16.78%

Average Drawdown

Average peak-to-trough decline

-70.53%

-67.34%

-3.19%

Ulcer Index

Depth and duration of drawdowns from previous peaks

30.69%

27.32%

+3.37%

Volatility

PACB vs. GRAB - Volatility Comparison

Pacific Biosciences of California, Inc. (PACB) has a higher volatility of 23.75% compared to Grab Holdings Limited (GRAB) at 8.97%. This indicates that PACB's price experiences larger fluctuations and is considered to be riskier than GRAB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


PACBGRABDifference

Volatility (1M)

Calculated over the trailing 1-month period

23.75%

8.97%

+14.78%

Volatility (6M)

Calculated over the trailing 6-month period

56.74%

24.51%

+32.23%

Volatility (1Y)

Calculated over the trailing 1-year period

88.70%

37.80%

+50.90%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

94.39%

59.83%

+34.56%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

84.71%

60.44%

+24.27%

Dividends

PACB vs. GRAB - Dividend Comparison

Neither PACB nor GRAB has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

PACB vs. GRAB - Financials Comparison

This section allows you to compare key financial metrics between Pacific Biosciences of California, Inc. and Grab Holdings Limited. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00M1.00B20222023202420252026
37.18M
955.00M
(PACB) Total Revenue
(GRAB) Total Revenue
Values in USD except per share items

Frequently Asked Questions


PACB and GRAB have a correlation of 0.29, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

PACB has higher volatility (23.75%) compared to GRAB (8.97%). In terms of maximum drawdown, PACB dropped -98.22% vs GRAB's -86.46%.

PACB currently has the higher Sharpe Ratio (0.12 vs -0.76), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for PACB and GRAB

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer